Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

You may also be interested in...

Brandicourt’s Message To Sanofi Investors: Grow, Build, Explore Options

CEO Olivier Brandicourt's multi-pronged strategy involves defending in core areas like diabetes, vaccines and rare diseases, building in consumer healthcare, oncology and multiple sclerosis and reviewing strategic alternatives in other areas, including animal health.

Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products

Bevy of new products like Novo Nordisk’s Tresiba offer some incremental improvements over older insulins, but in an increasingly crowded market, payers have the upper hand.

Sanofi’s Toujeo Is Approved, Now The Hard Part: Commercialization

Sanofi’s next-generation long-acting insulin will compete against an entrenched rival, the company’s own Lantus – a challenging proposition for any drug marketer, especially in the increasingly cost-conscious diabetes sector.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts